OFF-LABEL USE OF SECOND-GENERATION ANTIPSYCHOTICS

被引:0
|
作者
Spina, Edoardo [1 ,2 ]
Fava, Giuseppina [1 ]
Makos, Xenofon [1 ]
机构
[1] Univ Messina, Dept Clin & Expt Med & Pharmacol, Pharmacol Sect, Policlinico Univ,Via Consolare, I-98125 Messina, Italy
[2] IRCCS, Ctr Neurolesi BoninoPulejo, Messina, Italy
来源
CLINICAL NEUROPSYCHIATRY | 2009年 / 6卷 / 01期
关键词
Antipsychotics; Off label; Bipolar depression; Behavioral and psychological symptoms of dementia; Obsessive-compulsive disorder; Borderline personality disorder; Dopaminergic psychosis; Generalized anxiety disorder;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
All second-generation antipsychotics are licensed for the treatment of schizophrenia. Some of these agents are also approved for the treatment of acute mania and for maintenance therapy of bipolar disorder. In view of a broader spectrum of activity and a more favourable tolerability profile as compared to first-generation compounds, second generation antipsychotics are increasingly used oil-label for the treatment of many psychiatric conditions, either as monotherapy, or as an augmentation strategy. This article reviews the available data concerning the use of second generation antipsychotics in the most common off-label indications in adult and elderly psychiatric patients, such as bipolar depression, behavioural and psychological symptoms of dementia, obsessive-compulsive disorder, borderline personality disorder, dopaminergic psychosis and generalized anxiety disorder.
引用
收藏
页码:11 / 20
页数:10
相关论文
共 50 条
  • [41] Reduction of Off-Label Use of Antipsychotics in a Long Term Care Facility
    Burton, C. A.
    Thomas, C.
    Young, R.
    Na, C.
    Shepard, V.
    Shen, H.
    Ogar, J.
    Armstrong, J.
    Hadley, L.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2018, 66 : S273 - S273
  • [42] Reduction of Off-Label Use of Antipsychotics in a Long Term Care Facility
    Bieltz, Maureen
    Lantz, S.
    Whyte-Nagel, S.
    Zeigler, K.
    Tiesi, K.
    JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2018, 19 (03) : B21 - B22
  • [43] Off-label use of antipsychotics: when is the benefit/risk ratio favourable?
    Anand, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S212 - S212
  • [44] Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia
    Mallinger, JB
    Fisher, SG
    Brown, T
    Lamberti, JS
    PSYCHIATRIC SERVICES, 2006, 57 (01) : 133 - 136
  • [45] Factors Influencing the Use of Second-Generation Antipsychotics in Children with Psychosis
    Ramachandran, Sujith
    Banahan, Benjamin F., III
    Bentley, John P.
    West-Strum, Donna S.
    Patel, Amit S.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2016, 22 (08): : 948 - 957
  • [46] Risk of Breast Cancer in Association with the Use of Second-generation Antipsychotics
    Joo, Sung Woo
    Lee, Boung Chul
    Lee, Jungsun
    Seo, Gi Hyeon
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2022, 20 (04) : 675 - 684
  • [47] Off-label use in cardiac surgery ["Off-label use" in der Herzchirurgie]
    Fenger H.
    Löher A.
    Sindermann J.R.
    Scheld H.H.
    Schmidt C.
    Hoffmeier A.
    Zeitschrift für Herz-,Thorax- und Gefäßchirurgie, 2009, 23 (6) : 345 - 348
  • [48] Second-generation antipsychotics and the metabolic syndrome
    Prakash S. Masand
    Rajnish Mago
    Current Psychiatry Reports, 2005, 7 (3) : 153 - 154
  • [49] First- and Second-Generation Antipsychotics
    McEvoy, Joseph P.
    Zigman, Daniel
    Margolese, Howard C.
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2010, 55 (03): : 144 - 149
  • [50] Second-generation antipsychotics for anxiety disorders
    Depping, Anna M.
    Komossa, Katja
    Kissling, Werner
    Leucht, Stefan
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (12):